keyword
MENU ▼
Read by QxMD icon Read
search

BCG immunotherapy

keyword
https://www.readbyqxmd.com/read/29783018/tumor-inhibitory-effects-of-intravesical-ganoderma-lucidum-instillation-in-the-syngeneic-orthotopic-mb49-c57-bladder-cancer-mice-model
#1
J W M Yuen, D S Y Mak, E S Chan, M D I Gohel, C F Ng
ETHNOPHARMACOLOGICAL RELEVANCE: Ganoderma lucidum (GL) has been traditionally used in oriental medicine as superior health tonic, and there are numerous scientific evidences of its antitumorigenic activities. AIM OF THE STUDY: To evaluate the intravesical chemopreventive effects of ethanol extract of GL (GLe) on bladder cancer. MATERIALS AND METHODS: Intravesical therapy is defined as the direct instillation of a liquid drug into bladder through a catheter...
May 18, 2018: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/29770266/renal-granulomatosis-post-intravesical-bacillus-calmette-guerin-therapy-for-non-muscle-invasive-bladder-cancer
#2
Karen Tran-Harding, Rashmi T Nair, Halemane Ganesh
Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is a proven, effective treatment for intermediate- and high-risk non-muscle-invasive bladder cancer. Minor side effects are common and expected but systemic effects can occur in <5% of treated patients. We present a rare case of a 49-year-old male that presented with fever and chills after 3 weeks of intravesical BCG therapy post transurethral resection of bladder tumor. New renal lesions were present on contrast-enhanced computed tomography scan which was histologically proven to be necrotizing renal granulomatosis...
2018: Journal of Clinical Imaging Science
https://www.readbyqxmd.com/read/29755647/autologous-tumor-cells-bacillus-calmette-gu%C3%A3-rin-formalin-based-novel-breast-cancer-vaccine-induces-an-immune-antitumor-response
#3
María José Godoy-Calderón, Víctor Salazar, Eglys González-Marcano, Ana Federica Convit
Autologous cancer cell vaccines represent a multivalent patient-specific treatment. Studies have demonstrated that these immunotherapies should be combined with immunomodulators to improve results. We tested in breast cancer the antitumor effects of a 200 µg autologous tumor cells homogenate combined with 0.0625 mg of bacillus Calmette-Guérin (BCG), and 0.02% formalin. We used a 4T1 murine model of BALB/c receiving four weekly injections of either this vaccine or control treatments. The control treatments were either Phosphate Buffer Saline, BCG treated with formalin, or the tumor cells homogenate plus BCG alone...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29754838/-bcg-infection-following-intravesicular-immunotherapy-for-bladder-cancer
#4
REVIEW
L Levi, M Groh, N De Castro, A Bergeron, F Schlemmer
BACKGROUND: Bacille of Calmette et Guérin (BCG) immunotherapy is the most effective treatment for non-muscle-invasive bladder cancer. Yet, potentially severe localized or systemic mycobacterial infections can happen. STATE OF KNOWLEDGE: In a patient who underwent BCG instillation for bladder cancer, the diagnosis of BCG infection is usually suggested by more than 3 days of high-grade fever and systemic and/or local symptoms with no other plausible alternative diagnosis...
May 10, 2018: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/29745925/-mechanism-of-action-of-intravesical-bcg-biological-bases-and-clinical-applicability
#5
Joaquín A Carballido, María Rodríguez Monsalve
The therapeutic approaches developed around immune system modulation find the therapeutic contribution of intravesical Bacillus Calmette Guerin (BCG) for transitional cell bladder cancer an unquestionable example as a proof of concept of antitumor immunotherapy since more than 30 years ago. Intravesical immunotherapy for urothelial carcinomas is considered with periodic intravesical instillations schedules, and the one with longer historic development and wider diffusion is BCG in the form of suspension. BCG is a unique strain obtained from Mycobacterium bovis at the end of the first third of the XX century and represents the historically most successful immunotherapeutic modality of all tumors with a high level body of evidence...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29730950/emerging-intravesical-drugs-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#6
Jasper Crijnen, Theo M de Reijke
Bladder cancer (BC) is a severe health burden: it is the fifth most common malignancy in the world and has high recurrence and progression rates. Standard treatment starts with TURB followed by intravesical chemotherapy with Mitomycin C or immunotherapy with BCG. However, successful management still remains a challenge, because approximately 30% of patients have recurrence or progression within 5 years, and treatment has considerable side effects. Anticipating on the upcoming BCG shortage emphasizes, moreover, the necessity to develop and study novel treatments...
May 5, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29718990/a-multi-antigenic-mva-vaccine-increases-efficacy-of-combination-chemotherapy-against-mycobacterium-tuberculosis
#7
Stéphane Leung-Theung-Long, Charles-Antoine Coupet, Marie Gouanvic, Doris Schmitt, Aurélie Ray, Chantal Hoffmann, Huguette Schultz, Sandeep Tyagi, Heena Soni, Paul J Converse, Lilibeth Arias, Patricia Kleinpeter, Benoît Sansas, Khisimuzi Mdluli, Cristina Vilaplana, Pere-Joan Cardona, Eric Nuermberger, Jean-Baptiste Marchand, Nathalie Silvestre, Geneviève Inchauspé
Despite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strains resistant to antibiotics represents an urgent threat for global health that has prompted a search for alternative treatment regimens not subject to development of resistance. Immunotherapy constitutes a promising approach to improving current antibiotic treatments through engagement of the host's immune system...
2018: PloS One
https://www.readbyqxmd.com/read/29673806/the-challenges-of-bacillus-of-calmette-guerin-bcg-therapy-for-high-risk-non-muscle-invasive-bladder-cancer-treatment-in-older-patients
#8
Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco, PierFrancesco Bassi
OBJECTIVES: To evaluate the efficacy and safety of a tailored endovesical immunotherapy protocol with biweekly BCG for elderly Patients with high risk non muscle invasive bladder cancer (HG-NMIBC). MATERIALS AND METHODS: We retrospectively evaluated data from 200 patients older than 80 years newly diagnosed with HG-NMIBC: 100 (group 1) with multiple comorbidities (WHO PS 2-3, ASA score ≥3, Charlson Comorbidity index ≥3, GFR<60 mL/min) were treated with BCG induction course administered biweekly; 100 (group 2) with statistically significant better conditions were treated with standard weekly BCG therapy...
April 16, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29666128/prognostic-value-of-ki67-in-bcg-treated-non-muscle-invasive-bladder-cancer-a-meta-analysis-and-systematic-review
#9
Yuhui He, Ning Wang, Xiaofeng Zhou, Jianfeng Wang, Zhenshan Ding, Xing Chen, Yisen Deng
OBJECTIVES: The aim of this study was to explore the prognostic value of ki67 as a marker in patients with non-muscle invasive bladder cancer (NMIBC) treated with BCG. METHODS: Studies were systematically retrieved from the relevant databases (Web of Science, PubMed, Cochrane Library and Embase), and the expiry date was May 2017. The research steps referred to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. RESULTS: A total of 11 studies that complied with the inclusion criteria were included...
April 17, 2018: BMJ Open
https://www.readbyqxmd.com/read/29644393/treatment-of-carcinoma-in-situ-of-the-urinary-bladder-with-an-alpha-emitter-immunoconjugate-targeting-the-epidermal-growth-factor-receptor-a-pilot-study
#10
Michael E Autenrieth, Christof Seidl, Frank Bruchertseifer, Thomas Horn, Florian Kurtz, Benedikt Feuerecker, Calogero D'Alessandria, Christian Pfob, Stephan Nekolla, Christos Apostolidis, Saed Mirzadeh, Jürgen E Gschwend, Markus Schwaiger, Klemens Scheidhauer, Alfred Morgenstern
PURPOSE: Patients with carcinoma in situ (CIS) of the bladder refractory to bacillus Calmette-Guérin (BCG) treatment are usually treated with cystectomy. Therefore, new treatment options with preservation of the urinary bladder are needed. The objective of the study was to investigate the feasibility, safety and efficacy of a novel targeted alpha-emitter immunotherapy for CIS after BCG treatment failure. METHODS: A pilot study was conducted in 12 patients (age range 64-86 years, ten men, two women) with biopsy-proven CIS of the bladder refractory to BCG treatment...
April 11, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29576423/iatrogenic-pathology-of-the-urinary-bladder
#11
REVIEW
Antonio Lopez-Beltran, Rodolfo Montironi, Maria R Raspollini, Liang Cheng, George J Netto
Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder...
March 14, 2018: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/29552014/autoantibodies-may-predict-immune-related-toxicity-results-from-a-phase-i-study-of-intralesional-bacillus-calmette-gu%C3%A3-rin-followed-by-ipilimumab-in-patients-with-advanced-metastatic-melanoma
#12
Jessica Da Gama Duarte, Sagun Parakh, Miles C Andrews, Katherine Woods, Anupama Pasam, Candani Tutuka, Simone Ostrouska, Jonathan M Blackburn, Andreas Behren, Jonathan Cebon
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma. The first ICI to demonstrate clinical benefit, ipilimumab, targets cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4); however, the long-term overall survival is just 22%. More than 40 years ago intralesional (IL) bacillus Calmette-Guérin (BCG), a living attenuated strain of Mycobacterium bovis , was found to induce tumor regression by stimulating cell-mediated immunity following a localized and self-limiting infection...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29542328/waiting-in-the-wings-the-emerging-role-of-molecular-biomarkers-in-bladder-cancer
#13
Dafina Ilijazi, Mohammad Abufaraj, Melanie R Hassler, Iris E Ertl, David D'Andrea, Shahrokh F Shariat
Bladder cancer (BCa) is the fifth most frequently diagnosed cancer worldwide and is, in fact, the most expensive cancer on a per-patient to treat basis. There is a critical need to implement new tests into clinical practice to improve the quality of clinical care, decrease unnecessary invasive therapies and ultimately save costs. Currently, no molecular or genetic biomarker has been widely integrated into daily clinical practice. However, major milestones have been achieved in our understanding of the molecular alterations in BCa that will provide the basis for integrating molecular and genetic biomarkers into clinical decision making to guide management...
April 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/29454317/oxidative-damage-and-response-to-bacillus-calmette-gu%C3%A3-rin-in-bladder-cancer-cells-expressing-sialyltransferase-st3gal1
#14
Paulo F Severino, Mariana Silva, Mylene Carrascal, Nadia Malagolini, Mariella Chiricolo, Giulia Venturi, Roberto Barbaro Forleo, Annalisa Astolfi, Mariangela Catera, Paula A Videira, Fabio Dall'Olio
BACKGROUND: Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of non-muscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumor-associated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown. METHODS: The human bladder cancer (BC) cell line HT1376 strongly expressing the T antigen, was retrovirally transduced with the ST3GAL1 cDNA or with an empty vector, yielding the cell lines HT1376sT and HT1376T , that express, respectively, either the sT or the T antigens...
February 17, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29453645/emphasis-of-fas-fasl-gene-polymorphism-in-patients-with-non-muscle-invasive-bladder-cancer
#15
Cavit Ceylan, Sedat Yahşi, Serkan Doğan, Elife ÖztÜrk, Gulay Ceylan
BACKGROUND: Bladder cancer (BCa) is the seventh most common cancer among males worldwide. Some reliable markers in blood, urine, and tumor tissue, including clinicopathologic variables, molecular and inflammatory markers, gene polymorphisms, and tumor gene expression profiles are identified for predicting response to BCG immunotherapy in high-risk BCa patients. AIMS: We aimed to determine if FAS and FASL polymorphisms are associated with lack of response to BCG in patients with BCa...
February 16, 2018: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/29429897/role-of-immunotherapy-in-bacillus-calmette-gu%C3%A3-rin-unresponsive-non-muscle-invasive-bladder-cancer
#16
REVIEW
Neelam Mukherjee, Robert S Svatek, Ahmed M Mansour
Intravesical instillation of live attenuated bacillus Calmette-Guérin (BCG) is the gold standard for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). BCG-failures include a heterogenous population of patients who share a designation of disease recurrence or progression following BCG and include patients with complete unresponsiveness to BCG, patients who respond initially but develop relapse and, in some cases, patients who are intolerant to BCG due to side effects. Given the efficacy and relatively rapid approval of several monoclonal antibodies against PD-L1 or PD-1 for advanced and metastatic bladder cancer, the role of these checkpoint inhibitors in BCG-relapsing disease at various disease stages is under consideration...
March 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29414736/a-novel-cosmetic-and-clinically-practicable-laser-immunotherapy-for-facial-verruca-plana-intense-pulsed-light-combined-with-bcg-psn
#17
Fuhe Zhang, Lei Shi, Pei Liu, Linglin Zhang, Qianqian Wu, Bo Wang, Guolong Zhang, Peiru Wang, Feifang Zhou, Wei R Chen, Xiuli Wang
BACKGROUND: There is no alternative method to remove facial verruca plana and achieve better cosmetic effects. The present study is the first study to use intense pulsed light (IPL) as photothermal therapy (PTT) combined with intra-gluteal injection of bacillus calmette-guerin polysaccharide nucleic acid (BCG-PSN), which function as immunotherapy, contracting a new type of clinically available laser immunotherapy(LIT)for the treatment of facial verruca plana. The aim of this study was to evaluate the efficacy, cosmetic outcome, and adverse reactions of IPL combined with BCG-PSN for facial verruca plana...
February 4, 2018: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/29286018/miliary-pulmonary-infection-after-bcg-intravesical-instillation-a-rare-misdiagnosed-and-mistreated-complication
#18
Giorgio Calleris, Giancarlo Marra, Silvia Corcione, Marco Oderda, Chiara Cardellino, Sabrina Audagnotto, Bruno Frea, Francesco Giuseppe De Rosa, Paolo Gontero
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy decreases the progression risk of non-muscle-invasive bladder cancer, but potentially yields a broad spectrum of side effects. We report the case of a 73-year-old man affected by miliary pulmonary BCG infection, whose microbiological diagnosis was probably hindered by empiric fluoroquinolones, focusing on imaging and clinical work-up.
December 1, 2017: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/29273406/re-radical-cystectomy-bladder-removal-against-intravesical-bcg-immunotherapy-for-high-risk-non-muscle-invasive-bladder-cancer-bravo-a-protocol-for-a-randomised-controlled-feasibility-study
#19
https://www.readbyqxmd.com/read/29247502/immunotherapy-excluding-checkpoint-inhibitors-for-stage-i-to-iii-non-small-cell-lung-cancer-treated-with-surgery-or-radiotherapy-with-curative-intent
#20
REVIEW
Jianwei Zhu, Rui Li, Eva Tiselius, Raheleh Roudi, Olivia Teghararian, Chen Suo, Huan Song
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For patients with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. While several new agents have now entered phase III clinical trials, we felt a systematic review was needed to address the question of the effectiveness and safety of immunotherapy in patients with stages I to III NSCLC...
December 16, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
7100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"